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Background-—Elevated serum phosphorus might aggravate the effect of hypertension on mortality. The objective of this study was
to examine the joint effect of hypertension and serum phosphorus on the risk of mortality.
Methods and Results-—A large prospective (n=15 833), population-based cohort of participants from the National Health and
Nutritional Examination Survey III was examined to test potential synergism between hypertension, elevated serum phosphorus,
and the risk of mortality. Interaction on additive scale and multiplicative scale was estimated. After a median follow-up of
14.3 years, 1691 cases of cardiovascular mortality and 3875 cases of all-cause mortality were identiﬁed. Interaction was
observed between hypertension and elevated serum phosphorus on the additive scale for cardiovascular mortality (relative
excess risk due to interaction, 0.99, 95% CI: 0.06; 1.92, adjusted for age, gender, race, and estimated glomerular
ﬁltration rate). No statistically signiﬁcant interaction was found between hypertension and serum phosphorus for all-cause
mortality on the additive scale. No signiﬁcant interaction was detected on the multiplicative scale. In sensitivity analysis,
excluding participants who died in ﬁrst 2 years and adjustment for additional confounders resulted in essentially similar
ﬁndings.
Conclusions-—The joint effect of hypertension and elevated serum phosphorus was larger than the sum of the independent effects
on cardiovascular mortality but not on all-cause mortality. Future studies should investigate whether controlling elevated serum
phosphorus in hypertensive individuals helps in prevention of extra risk of cardiovascular mortality. ( J Am Heart Assoc. 2015;4:
e001706 doi: 10.1161/JAHA.114.001706)
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H ypertension is a global public health problem. It is oneof the major causes of premature deaths worldwide,
killing nearly 8 million people every year, and 92 million
disabled years are attributed to hypertension.1 Lowering
blood pressure reduces risk of cardiovascular morbidity and
mortality, and all-cause mortality.2 Besides controlling hyper-
tension itself, understanding other modiﬁable risk factors,
which might enhance complications in hypertensive individ-
uals, is important.
Recently, a number of observational studies have shown an
independent relationship between elevated serum phospho-
rus and risks of cardiovascular as well as all-cause mortality in
the general population.3,4 Impaired intestinal phosphate
absorption, renal phosphate reabsorption, and phosphate
metabolism might elevate serum phosphorus level.5 Elevated
serum phosphorus increases mortality risk through vascular
injury and calciﬁcation.6,7 Among hypertensive individuals, it
is well established that the left ventricular wall thickens in
response to elevated blood pressure as a compensatory
mechanism to minimize wall stress.8 Subsequently, after a
series of poorly characterized events (“transition to failure”),
the left ventricular ejection fraction declines and the risk of
mortality increases. It is possible that, in individuals with both
elevated serum phosphorus and hypertension, impaired
vessel walls (resulting from elevated serum phosphorus)
together with high blood pressure might aggravate the
response of the left ventricular wall and ultimately the risk
of mortality.9 Therefore, the joint effect of hypertension and
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elevated serum phosphorus on mortality might be larger than
the sum of their independent effects, particularly on cardio-
vascular mortality.
This hypothesis was tested in a large, population-based,
prospective cohort of adult general population by examining
the joint effect of hypertension and elevated serum phospho-
rus on risk of cardiovascular and all-cause mortality.
Methods
Study Design and Population
Data of subjects participating in the Third National Health and
Nutritional Examination Survey 1988–1994 (NHANES III), a
nationally representative sample of civilian noninstitutional-
ized US population was used. Brieﬂy, the NHANES surveys are
cross-sectional, multistage, stratiﬁed, clustered probability
samples of the noninstitutionalized US civilian population. The
details of the study can be found at http://www.cdc.gov/
nchs/nhanes.htm. For the current study, data of participants
older than 18 years with complete data on blood pressure,
serum phosphorus and mortality, and other relevant covari-
ates (n=15 833) were examined. The National Centres for
Health Statistics Ethics Review Board approved the study
protocol, and each participant provided written informed
consent.
Measurements
Blood pressure and hypertension
Blood pressure was measured by a trained research assistant 3
times during the in-home visits and 3 additional times by a
trained clinician during the visit to the mobile examination
clinic. In both settings, blood pressures were measured with
the participant in the sitting position after 5 minutes of rest.
For systolic and diastolic blood pressure, separately, the
second and third measurements from each visit were aver-
aged. Hypertension was deﬁned as self-reported history of
hypertension, measured systolic blood pressure ≥140 mm Hg,
measured diastolic blood pressure ≥90 mm Hg, or self-
reported use of blood pressure medications.10
Measurement of serum phosphorus
Serum phosphorus was measured using a Hitachi model 737
multichannel analyzer (Boehringer Mannheim Diagnostics) by
reacting inorganic phosphorus with ammonium molybdate in
an acidic solution to form ammonium phosphomolybdate,
which was quantiﬁed in the UV range (340 nm) through the
use of a sample-blanked end-point method.11 Elevated serum
phosphorus was deﬁned as serum phosphorus concentration
≥1.36 mmol/L (4.2 mg/dL).
Mortality follow-up
Adult NHANES III participants were followed for mortality
through December 31, 2006. Probabilistic matching was used
to link NHANES III participants with the National Death Index
to ascertain vital status. Matching was based on 12 identiﬁers
for each participant (eg, Social Security number, gender, and
date of birth), leading to correct matching in 96.1% of
deceased participants and 99.4% of living participants.
Cardiovascular mortality was deﬁned by International
Classiﬁcation of Diseases, Tenth Edition, Clinical Modiﬁcation
codes 100 to 178 derived from death certiﬁcate data.
Covariates
Information on age, gender, race, cigarette smoking, history of
cardiovascular disease, and family income was self-reported
by the participants and was obtained via interview during in-
home visits. Socioeconomic status was assessed by the
poverty income ratio, which is the ratio of family income to
the federal poverty threshold (speciﬁc to the year of the
interview).
Height and weight were measured using standardized
methods, and body mass index was calculated as weight in
kilograms divided by height in meters squared. Serum
creatinine, cholesterol, and glucose were measured as
previously described.12 Kidney function was assessed from
estimated glomerular ﬁltration rate (eGFR). Glomerular ﬁltra-
tion rate was estimated using the Chronic Kidney Disease
Epidemiology Collaboration creatinine equation after calibrat-
ing serum creatinine values to Cleveland Clinic reference
values.13 Diabetes was deﬁned in accordance with the criteria
of the American Diabetes Association (ie, fasting plasma
glucose ≥7 mmol/L [126 mg/dL] and/or current use of
insulin or oral hypoglycemic agents).14
Statistical Analysis
A Cox proportional hazards model was used to estimate
hazard ratios of cardiovascular and all-cause mortality with
95% CI. Because eGFR is related to serum phosphorus and
hypertension, relationship between hypertension, elevated
serum phosphorus, and mortality was examined in a multi-
variate analysis adjusted for eGFR along with age, gender, and
race. Proportional hazards assumption was evaluated by
Sch€onfeld’s residuals and by inspection of log-log plots.
Given that the nature of a joint effect can be additive or
multiplicative,15,16 the joint effect of hypertension and
elevated serum phosphorus on risk of mortality was investi-
gated by testing interaction between hypertension and
elevated serum phosphorus on an additive and multiplicative
scale. Additive interaction indicates that an effect is more
than additive when the risk ratios found are greater than the
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sum of individual risk ratios. Interaction on the additive scale
was assessed by calculating the relative excess risk caused by
interaction (RERI), using the algorithm of Andersson et al.17
RERI was calculated as (HR11HR10HR01)+1, where HR11 is
the hazard ratio for both risk factors present, HR10 is the
hazard ratio for hypertension but no elevated serum phos-
phorus, and HR01 is the hazard ratio for no hypertension but
elevated serum phosphorus. RERI effects were considered
signiﬁcant when 95% CI of RERI did not contain zero.
Interaction on the multiplicative scale was assessed by
comparing multiplicative models with and without an interac-
tion term using the log-likelihood ratio test.
Sensitivity analyses were performed to test the robustness
of our ﬁndings. First, to account for possible reverse
causation, we performed analyses after excluding participants
who died in the ﬁrst 2 years of follow-up. Second, because
use of diuretic antihypertensive medication can affect blood
pressure, risk of mortality, as well as affect serum phosphorus
levels, we performed analyses after excluding participants
who were on diuretic medication. Third, we additionally
adjusted for dietary phosphorus intake. Finally, interactions
were tested after adjustment for additional covariates in
association between hypertension, elevated serum phospho-
rus, and mortality. Models were additionally adjusted for
socioeconomic status, body mass index, smoking, cardiovas-
cular disease history, diabetes, serum cholesterol, and vitamin
D. In accordance with NHANES analytic guidelines, NHANES
III speciﬁc sampling weights were incorporated to account for
its complex survey design (http://www.cdc.gov/nchs/tuto-
rials/nhanes/stata_tips.htm). All analyses were performed
using Stata Statistical Software (version 13.0; Stata Corp).
Results
A total of 1691 cases of cardiovascular mortality and 3875
cases of all-cause mortality were identiﬁed over a median
follow-up of 14.3 years. Baseline characteristics of the study
population are shown in Table 1. The HRs of hypertension and
elevated serum phosphorus, adjusted for age, gender, race,
and eGFR, are shown in Table 2. Hypertension and elevated
serum phosphorus separately were signiﬁcantly associated
with the risk of cardiovascular and all-cause mortality. The
joint effect of hypertension and elevated serum phosphorus
on the risk of mortality is shown in Table 3, and is visualized
Table 1. Baseline Characteristics of Hypertensive Cases, Elevated Serum Phosphorus Cases, Hypertensive Cases With Elevated
Serum Phosphorus, and Entire Cohort
Characteristics
Hypertension
(n=5850)
Elevated Serum
Phosphorus
(n=1325)
Hypertension and Elevated
Serum Phosphorus
(n=455)
Entire Cohort
(N=15 833)
Age, y 54 (0.5) 43 (0.6) 56 (0.9) 44 (0.4)
Gender (male), % 49 37 33 48
Race, %
Whites 77 70 72 76
African Americans 13 15 15 11
Mexican Americans 4 7 6 5
Others 6 8 8 8
Serum phosphorus, mmol/L 1.10 (<0.1) 1.43 (<0.1) 1.44 (0.1) 1.11 (<0.1)
Poverty (yes), % 13 19 19 12
Smoking, % 56 54 57 54
CVD history (yes), % 13 6 14 6
Body mass index, kg/m2 29 (0.2) 26 (0.3) 29 (0.3) 27 (0.1)
SBP, mm Hg 138 (0.6) 121 (0.9) 141 (1.0) 122 (0.4)
DBP, mm Hg 80 (0.2) 73 (0.4) 79 (0.6) 74 (0.2)
Diabetes mellitus (yes), % 13 7 16 7
Serum glucose, mmol/L 5.83 (0.1) 5.24 (0.1) 6.03 (0.1) 5.36 (<0.1)
Serum cholesterol, mmol/L 5.71 (<0.1) 5.34 (0.1) 5.77 (0.1) 5.29 (<0.1)
eGFR, mL/min per 1.73 m2 85 (0.6) 93 (1.2) 81 (1.4) 94 (0.5)
Continuous variables are presented as mean (standard error), categorical variables are presented as percentages. CVD indicates cardiovascular disease; DBP, diastolic blood pressure;
eGFR, estimated glomerular ﬁltration rate; SBP, systolic blood pressure.
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in Figure for cardiovascular mortality. The joint effect of
hypertension and elevated serum phosphorus on the risk of
cardiovascular mortality and all-cause mortality was
(HR=2.80, 95% CI: 2.09; 3.73) and (HR=1.76, 95% CI: 1.49;
2.07), respectively. For cardiovascular mortality, interaction
was observed between hypertension and elevated serum
phosphorus on the additive scale (RERI=0.99, 95% CI: 0.06;
1.92, adjusted for age, gender, race, and eGFR), suggesting
that the joint effect of hypertension and elevated serum
phosphorus is stronger than is the sum of the independent
effects of individual risk factor. With respect to all-cause
mortality, no clear evidence of interaction was observed
between hypertension and elevated serum phosphorus on the
additive scale (RERI=0.16, 95% CI: 0.25; 0.57, adjusted for
age, gender, race, and eGFR). No substantial interaction was
observed on the multiplicative scale between hypertension
and elevated serum phosphorus either for cardiovascular
mortality (P=0.130, log-likelihood ratio test) or all-cause
mortality (P=0.741, log-likelihood ratio test).
The joint effect of hypertension and elevated serum
phosphorus on the risk of cardiovascular mortality and all-
cause mortality after excluding participants who died in the
ﬁrst 2 years of follow-up is shown in Table 4. In this case,
RERI for cardiovascular mortality was signiﬁcant (RERI=1.21,
95% CI: 0.26; 2.17) and not for all-cause mortality (RERI=0.17,
95% CI: 0.27; 0.62, adjusted for age, gender, race, and
eGFR). After excluding participants on diuretic medication,
RERI for cardiovascular mortality was statistically signiﬁcant
(RERI=1.31, 95% CI: 0.30; 2.33) but not for all-cause mortality
(RERI=0.20, 95% CI: 0.22; 0.62). After adjusting for dietary
phosphorus intake, RERI for cardiovascular mortality was
statistically signiﬁcant (RERI=1.10, 95% CI: 0.09; 2.10) and
not for all-cause mortality (RERI=0.18, 95% CI: 0.22; 0.58).
Results after additional adjustment for socioeconomic status,
body mass index, smoking, history of cardiovascular disease,
diabetes, serum cholesterol, and vitamin D are shown in
Table 4. In this case, RERI for cardiovascular mortality,
although not statistically signiﬁcant, was positive and tended
to be higher (RERI=0.88, 95% CI: 0.07, 1.83) compared to
Table 2. Crude Incidence Rate and Adjusted* Hazard Ratios
of Cardiovascular and All-Cause Mortality for Hypertension
and Elevated Serum Phosphorus
Risk Factors
Cases
(n)
Crude
Incidence
Rate Hazard Ratio P Value
Cardiovascular mortality
Hypertension 1234 17.7 1.86 (1.48 to 2.34) <0.001
Elevated
serum
phosphorus
141 7.8 1.45 (1.12 to 1.88) 0.005
All-cause mortality
Hypertension 2551 36.6 1.45 (1.25 to 1.67) <0.001
Elevated
serum
phosphorus
296 16.4 1.22 (1.05 to 1.41) 0.01
*Adjusted for age, gender, race, and estimated glomerular ﬁltration rate.
Table 3. Crude Incidence Rate and Adjusted* Hazard Ratios of Cardiovascular and All-Cause Mortality for Joint Effect of
Hypertension and Elevated Serum Phosphorus
Risk Factors Cases (n) Crude Incidence Rate Hazard Ratio P Value
Cardiovascular mortality
No hypertension
No elevated serum phosphorus 422 3.3 Reference
Elevated serum phosphorus 33 2.6 1.01 (0.65 to 1.56) 0.97
Hypertension
No elevated serum phosphorus 1124 17.5 1.80 (1.41 to 2.28) <0.001
Elevated serum phosphorus 108 19.8 2.80 (2.09 to 3.73) <0.001
All-cause mortality
No hypertension
No elevated serum phosphorus 1222 9.5 Reference
Elevated serum phosphorus 97 7.7 1.16 (0.89 to 1.51) 0.26
Hypertension
No elevated serum phosphorus 2340 36.4 1.44 (1.24 to 1.67) <0.001
Elevated serum phosphorus 199 36.4 1.76 (1.49 to 2.07) <0.001
*Adjusted for age, gender, race, and estimate glomerular ﬁltration rate.
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all-cause mortality (RERI=0.10, 95% CI: 0.35; 0.56). The
interactions on the multiplicative scale were not signiﬁcant in
either of the sensitivity analyses.
Discussion
In this prospective study, our ﬁndings suggest that regarding
cardiovascular mortality the joint effect of hypertension and
elevated serum phosphorus is larger than the sum of their
individual effects but not regarding all-cause mortality. These
ﬁndings suggest that controlling serum phosphorus levels in
hypertensive individuals may lead to an extra risk reduction
regarding cardiovascular mortality.
Interaction in epidemiology tests whether the joint effect
of 2 risk factors on a certain outcome differs from the sum or
product of their independent effects. Therefore, interaction
can be measured on an additive or a multiplicative scale.
Interaction on the additive scale indicates the extent to which
the observed risk for disease in those with both risk factors is
greater (synergism) or lower (antagonism) than the sum of
individual risk ratios of each risk factor separately. Interaction
on the multiplicative scale concerns whether the risk for
disease in those with both risk factors was greater or lower
than was the multiplied risk ratios of each risk factor
alone.17,18 It is possible that the interaction is present only
on 1 scale or both scales. Although there is no consensus on
whether the additive or multiplicative scale is the most
appropriate, additive interaction may be of more relevance
from the viewpoint of translating epidemiological ﬁndings into
prevention of disease events, as it is readily translated into
impact of intervention in terms of absolute number of
preventable outcomes.19 The recent STROBE Statement
advises to report interaction analyses on an additive and
multiplicative scale 20 when evaluating joint effect of expo-
sures. We, therefore, presented interaction results on both an
additive and multiplicative scale. Moreover, it allows us to
compare our results with existing literature where conven-
tionally interaction is reported on a multiplicative scale.
The implications of ﬁnding interaction on the additive scale
between hypertension and elevated serum phosphorus and
the risk of cardiovascular mortality may suggest that these
risk factors share a common pathway in the pathogenesis of
cardiovascular mortality, and that combining serum phospho-
rus and blood pressure lowering may have an extra risk
reduction effect in preventing cardiovascular mortality. Some
earlier studies had reported inverse association between high
dietary serum phosphorus intake and risk of hyperten-
sion.21,22 However, in these studies either the main source
of high serum phosphorus was dairy products/leafy vegeta-
bles or only high serum phosphorus from dairy products was
associated with a reduced risk of hypertension. Dairy
products and leafy vegetables are known to be rich in other
.
.
Hypertension
- Elevated serum phosphorus
- No Elevated serum phosphorus
No hypertension
- Elevated serum phosphorus
- No Elevated serum phosphorus
Risk_factors
2.80 (2.09, 3.73)
1.80 (1.41, 2.28)
1.01 (0.65, 1.56)
1.00 (1.00, 1.00)
Hazards_ratio (95% CI)
Risk of cardiovascular mortality (hazards ratio on log scale) 
1.1 5
Figure. Joint and individual effects of hypertension and elevated serum phosphorus on the risk of
cardiovascular mortality.
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nutrients such as magnesium, calcium, and potassium and are
effective in reducing risk of hypertension,23 which might
explain these ﬁndings. No previous study has formally
examined the joint effect of hypertension and elevated serum
phosphorus on the risk of mortality. Only 1 study by Tonelli
et al tested interaction between serum phosphorus and
hypertension while examining the independent effect of
serum phosphorus on mortality in the general population.3
Tonelli et al found no joint effect of hypertension and elevated
serum phosphorus on risk of mortality. Interaction, however,
was tested on a multiplicative scale only. In our study,
interaction of risk factors was tested on both an additive and
a multiplicative scale, and it was found that interaction
between hypertension and elevated serum phosphorus was
present on the additive, but not the multiplicative, scale.
The results obtained in sensitivity analyses corroborate
with our main ﬁndings. We separately accounted for some of
the factors that might affect serum phosphorus levels and risk
of mortality (eg, dietary phosphorus intake, hypertensive
medication use, and renal function). Results were essentially
similar after accounting for these factors. Unfortunately,
NHANES-III did not collect information on factors that tightly
regulate phosphate metabolism (eg, ﬁbroblast growth factor
23 or intact parathyroid hormone measurement) and, there-
fore, it was not possible to investigate the effect of phosphate
metabolism on our ﬁndings. However, it should be noted that
the aim of this study was not to investigate the causes of
elevated serum phosphorus but to investigate the risk of
mortality when individuals have elevated serum phosphorus
as well as hypertension. After adjustment for additional
covariates, the RERI for cardiovascular mortality was not
statistically signiﬁcant, but it was positive and indicative of
joint effect. The low power for RERI after adjustment for
additional covariates might be because not all individuals in
the study had complete information on all of the covariates.
Therefore, adjustment for additional covariates resulted in
loss of a substantial number of individuals with elevated
serum phosphorus and hypertension (13%).
Our study has a number of strengths. The major strength
of this analysis is that it was conducted using data from a
Table 4. Adjusted Hazard Ratios of Cardiovascular and All-Cause Mortality for Joint Effect of Hypertension and Elevated Serum
Phosphorus
Risk Factors
After Exclusion Those Who Died
in First 2 Years
After Exclusion Those Who Used
Diuretics
Adjusting for Additional
Covariates*
Adjusting for Dietary Phosphorus
Intake†
Hazard Ratio P Value Hazard Ratio P Value Hazard Ratio P Value Hazard Ratio P Value
Cardiovascular mortality
No hypertension
No elevated serum
phosphorus
Reference Reference Reference Reference
Elevated serum
phosphorus
0.93 (0.56 to 1.54) 0.78 1.08 (0.67 to 1.74) 0.76 0.92 (0.53 to 1.60) 0.77 0.98 (0.58 to 1.66) 0.94
Hypertension
No elevated serum
phosphorus
1.77 (1.40 to 2.23) <0.001 1.70 (1.31 to 2.21) <0.001 1.67 (1.31 to 2.15) <0.001 1.87 (1.47 to 2.37) <0.001
Elevated serum
phosphorus
2.91 (2.13 to 3.98) <0.001 3.10 (2.27 to 4.22) <0.001 2.48 (1.82 to 3.37) <0.001 2.94 (2.24 to 3.87) <0.001
All-cause mortality
No hypertension
No elevated serum
phosphorus
Reference Reference Reference Reference
Elevated serum
phosphorus
1.18 (0.88 to 1.58) 0.27 1.23 (0.93 to 1.64) 0.14 1.12 (0.83 to 1.51) 0.46 1.14 (0.88 to 1.47) 0.32
Hypertension
No elevated serum
phosphorus
1.44 (1.23 to 1.69) <0.001 1.45 (1.24 to 1.71) <0.001 1.36 (1.15 to 1.61) <0.001 1.48 (1.27 to 1.71) <0.001
Elevated serum
phosphorus
1.79 (1.48 to 2.17) <0.001 1.89 (1.56 to 2.28) <0.001 1.58 (1.27 to 1.97) <0.001 1.80 (1.52 to 2.12) <0.001
*Adjusted for age, gender, race, estimated glomerular ﬁltration rate, socioeconomic status, smoking, body mass index, history of cardiovascular disease, diabetes, serum cholesterol, and
vitamin D.
†Adjusted for age, gender, race, estimated glomerular ﬁltration rate, and dietary phosphorus intake/day.
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large, well-characterized cohort of general population. The
long-term mortality data are also a signiﬁcant strength.
Potential confounders of the association between hyperten-
sion, elevated serum phosphorus, and mortality were carefully
considered. The study also has some limitations. Data were
only available for onetime assessment of both hypertension
and elevated serum phosphorus. Therefore, bias may have
been introduced because of risk factor levels that may have
changed after baseline measurements. Moreover, data in this
study were collected about 20 years ago. Given the changes
in health behaviors, disease awareness, and type of antihy-
pertensive medication use in last 20 years, prevalence and
incidence of hypertension and elevated serum phosphorus
might have changed. However, we believe that the mecha-
nism behind the joint effect of hypertension and serum
phosphorus is unlikely to have changed. Like previous
studies,24 we also found increased risk of cardiovascular-
related mortality from elevated serum phosphorus in men but
not women (data not shown). Because the main aim of this
study was to investigate the joint effect of elevated serum
phosphorus and hypertension, and there were a limited
number of participants with both elevated serum phosphorus
and hypertension, we could not investigate whether their joint
effect differs by sex. It should be investigated in future
studies with a larger sample size of participants with both
elevated serum phosphorus and hypertension. Finally, as for
all observational studies, the present ﬁndings do not conclu-
sively demonstrate that the joint effect of hypertension and
serum phosphorus for the risk of cardiovascular mortality is
causal.
A large body of evidence exists regarding excess risk of
mortality risk in kidney disease patients who have high levels
of serum phosphorus.25–28 Therefore, clinical management of
serum phosphorus is a priority in kidney disease patients.
Recently, suggestion has been made to control dietary intake
of phosphorus-containing food.6 However, there are no
established guidelines for serum phosphorus control in
hypertensive individuals. Managing causes of elevated serum
phosphorus and thereby controlling an existing elevated
serum phosphorus level in hypertensive individuals may be a
relevant therapeutic target in preventing excess risk of
cardiovascular mortality. Future studies, however, should
conﬁrm causality of the relationship between simultaneous
existence of serum phosphorus and hypertension and the risk
of cardiovascular mortality.
In conclusion, our study revealed that the joint effect of
hypertension and elevated serum phosphorus is larger than
the sum of their individual effects on cardiovascular mortality,
but not in case of all-cause mortality. Future studies should
investigate whether controlling elevated serum phosphorus in
hypertensive individuals helps in prevention of extra risk of
cardiovascular mortality.
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